Venetoclax is a potent BCL-2 selective BH3-mimetic that is clinically approved for use in chronic lymphocytic leukemia and treatment of patients with acute myeloid leukemia who are aged or unmet for intensive induction chemotherapy [45]. The gene discussed is BCL2; the disease is acute myeloid leukemia.